Paraneoplastic disorders of the nervous system.
Autoantibody
Immune checkpoint inhibitor
Limbic encephalitis
MRI
PET
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
26
01
2021
accepted:
16
04
2021
revised:
13
04
2021
pubmed:
28
4
2021
medline:
5
11
2021
entrez:
27
4
2021
Statut:
ppublish
Résumé
This article on paraneoplastic neurologic disorders provides an update on the diagnostic approach, utility and pitfalls of autoantibody testing and emerging settings in which these disorders are encountered. Recognition of the clinical and neuroimaging features accompanying paraneoplastic neurologic disorders is crucial to select those at highest risk who need neural antibody testing and screening for cancer. Cursory knowledge of the antibody assay methodology being ordered is important as the false positive rate varies by the technique utilized for detection. Antibodies can generally be stratified by the location of the target antigen (intraceullar versus cell-surface/synaptic) which informs frequency of cancer association, treatment response and prognosis. The therapeutic approach generally involves detection of the underlying cancer and combinations of oncologic treatments and immunosuppressant medications. The occurrence of paraneoplastic autoimmune neurologic disorders in novel settings, such as with immune checkpoint inhibitor use, has improved understanding of their pathogenesis and increased the likelihood neurologists will encounter such patients in their practice.
Identifiants
pubmed: 33904967
doi: 10.1007/s00415-021-10570-1
pii: 10.1007/s00415-021-10570-1
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4899-4907Informations de copyright
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157–165. https://doi.org/10.1016/S1474-4422(12)70310-1
doi: 10.1016/S1474-4422(12)70310-1
pubmed: 23290630
pmcid: 3563251
Armangue T, Spatola M, Vlagea A, Mattozzi S, Carceles-Cordon M, Martinez-Heras E, Llufriu S, Muchart J, Erro ME, Abraira L, Moris G, Monros-Gimenez L, Corral-Corral I, Montejo C, Toledo M, Bataller L, Secondi G, Arino H, Martinez-Hernandez E, Juan M, Marcos MA, Alsina L, Saiz A, Rosenfeld MR, Graus F, Dalmau J, Spanish Herpes Simplex Encephalitis Study G (2018) Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 17(9):760–772. https://doi.org/10.1016/S1474-4422(18)30244-8
doi: 10.1016/S1474-4422(18)30244-8
pubmed: 30049614
pmcid: 6128696
Flanagan EP (2020) Paraneoplastic disorders of the nervous system. Continuum (Minneap Minn) 26(6):1602–1628. https://doi.org/10.1212/CON.0000000000000941
doi: 10.1212/CON.0000000000000941
Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16(9):535–548. https://doi.org/10.1038/s41571-019-0194-4
doi: 10.1038/s41571-019-0194-4
pubmed: 30867573
Hara M, Arino H, Petit-Pedrol M, Sabater L, Titulaer MJ, Martinez-Hernandez E, Schreurs MW, Rosenfeld MR, Graus F, Dalmau J (2017) DPPX antibody-associated encephalitis: main syndrome and antibody effects. Neurology 88(14):1340–1348. https://doi.org/10.1212/WNL.0000000000003796
doi: 10.1212/WNL.0000000000003796
pubmed: 28258082
pmcid: 5379928
Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, Appendino JP, Lucchinetti CF, Matsumoto JY, Pittock SJ, Sandroni P, Tippmann-Peikert M, Wirrell EC, McKeon A (2014) DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 83(20):1797–1803. https://doi.org/10.1212/WNL.0000000000000991
doi: 10.1212/WNL.0000000000000991
pubmed: 25320100
pmcid: 4240433
Escudero D, Guasp M, Arino H, Gaig C, Martinez-Hernandez E, Dalmau J, Graus F (2017) Antibody-associated CNS syndromes without signs of inflammation in the elderly. Neurology 89(14):1471–1475. https://doi.org/10.1212/WNL.0000000000004541
doi: 10.1212/WNL.0000000000004541
pubmed: 28878050
pmcid: 5631166
Budhram A, Britton JW, Liebo GB, Dubey D, Zekeridou A, Flanagan EP, McKeon A, Pittock SJ, Braksick SA, Zalewski NL (2020) Use of diffusion-weighted imaging to distinguish seizure-related change from limbic encephalitis. J Neurol 267(11):3337–3342. https://doi.org/10.1007/s00415-020-10007-1
doi: 10.1007/s00415-020-10007-1
pubmed: 32583056
Spatola M, Petit-Pedrol M, Simabukuro MM, Armangue T, Castro FJ, Barcelo Artigues MI, Julia Benique MR, Benson L, Gorman M, Felipe A, Caparo Oblitas RL, Rosenfeld MR, Graus F, Dalmau J (2017) Investigations in GABAA receptor antibody-associated encephalitis. Neurology 88(11):1012–1020. https://doi.org/10.1212/WNL.0000000000003713
doi: 10.1212/WNL.0000000000003713
pubmed: 28202703
pmcid: 5384834
Flanagan EP, Hinson SR, Lennon VA, Fang B, Aksamit AJ, Morris PP, Basal E, Honorat JA, Alfugham NB, Linnoila JJ, Weinshenker BG, Pittock SJ, McKeon A (2017) Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol 81(2):298–309. https://doi.org/10.1002/ana.24881
doi: 10.1002/ana.24881
pubmed: 28120349
Vogrig A, Muniz-Castrillo S, Joubert B, Picard G, Rogemond V, Marchal C, Chiappa AM, Chanson E, Skowron F, Leblanc A, Ducray F, Honnorat J (2020) Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry 91(7):772–778. https://doi.org/10.1136/jnnp-2020-323055
doi: 10.1136/jnnp-2020-323055
pubmed: 32312871
Vernino S, Tuite P, Adler CH, Meschia JF, Boeve BF, Boasberg P, Parisi JE, Lennon VA (2002) Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 51(5):625–630. https://doi.org/10.1002/ana.10178
doi: 10.1002/ana.10178
pubmed: 12112110
Zekeridou A, Kryzer T, Guo Y, Hassan A, Lennon V, Lucchinetti CF, Pittock S, McKeon A (2019) Phosphodiesterase 10A IgG: a novel biomarker of paraneoplastic neurologic autoimmunity. Neurology 93(8):e815–e822. https://doi.org/10.1212/WNL.0000000000007971
doi: 10.1212/WNL.0000000000007971
pubmed: 31315972
pmcid: 6711657
Flanagan EP, Kotsenas AL, Britton JW, McKeon A, Watson RE, Klein CJ, Boeve BF, Lowe V, Ahlskog JE, Shin C, Boes CJ, Crum BA, Laughlin RS, Pittock SJ (2015) Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol Neuroinflamm 2(6):e161. https://doi.org/10.1212/NXI.0000000000000161
doi: 10.1212/NXI.0000000000000161
pubmed: 26468474
pmcid: 4592539
Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, Farooque P, Gelfand JM, Geschwind MD, Hirsch LJ, Somerville E, Lang B, Vincent A, Leite MI, Waters P, Irani SR, Faciobrachial Dystonic Seizures Study G (2018) The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 141(2):348–356. https://doi.org/10.1093/brain/awx323
doi: 10.1093/brain/awx323
pubmed: 29272336
Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, Saiz A, Meneses P, Rosenfeld MR (2004) Clinical analysis of anti-Ma2-associated encephalitis. Brain 127(Pt 8):1831–1844. https://doi.org/10.1093/brain/awh203
doi: 10.1093/brain/awh203
pubmed: 15215214
Salvarani C, Brown RD Jr, Christianson TJH, Huston J 3rd, Ansell SM, Giannini C, Hunder GG (2018) Primary central nervous system vasculitis associated with lymphoma. Neurology 90(10):e847–e855. https://doi.org/10.1212/WNL.0000000000005062
doi: 10.1212/WNL.0000000000005062
pubmed: 29429967
Graus F, Arino H, Dalmau J (2014) Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood 123(21):3230–3238. https://doi.org/10.1182/blood-2014-03-537506
doi: 10.1182/blood-2014-03-537506
pubmed: 24705493
pmcid: 4046430
Madhavan AA, Carr CM, Morris PP, Flanagan EP, Kotsenas AL, Hunt CH, Eckel LJ, Lindell EP, Diehn FE (2020) Imaging review of paraneoplastic neurologic syndromes. Am J Neuroradiol 41(12):2176–2187. https://doi.org/10.3174/ajnr.A6815
doi: 10.3174/ajnr.A6815
pubmed: 33093137
pmcid: 7963261
Dubey D, Wilson MR, Clarkson B, Giannini C, Gandhi M, Cheville J, Lennon VA, Eggers S, Devine MF, Mandel-Brehm C, Kryzer T, Hinson SR, Khazaie K, Hales C, Kattah J, Pavelko KD, Andrews P, Eaton JE, Jitprapaikulsan J, Mills JR, Flanagan EP, Zekeridou A, Leibovich B, Fryer J, Torre M, Kaufman C, Thoreson JB, Sagen J, Linnoila JJ, DeRisi JL, Howe CL, McKeon A, Pittock SJ (2020) Expanded Clinical Phenotype, Oncological Associations, and immunopathologic insights of paraneoplastic kelch-like protein-11 encephalitis. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2020.2231
doi: 10.1001/jamaneurol.2020.2231
pubmed: 32744608
pmcid: 7653501
Mandel-Brehm C, Dubey D, Kryzer TJ, O’Donovan BD, Tran B, Vazquez SE, Sample HA, Zorn KC, Khan LM, Bledsoe IO, McKeon A, Pleasure SJ, Lennon VA, DeRisi JL, Wilson MR, Pittock SJ (2019) Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis. N Engl J Med 381(1):47–54. https://doi.org/10.1056/NEJMoa1816721
doi: 10.1056/NEJMoa1816721
pubmed: 31269365
pmcid: 6800027
Madhavan A, Carr CM, Krecke KN, Wood CP, McKeon A, Dubey D (2021) Association between paraneoplastic rhombencephalitis and hypertrophic olivary degeneration. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2020-325569
doi: 10.1136/jnnp-2020-325569
pubmed: 34285066
Hutchinson M, Waters P, McHugh J, Gorman G, O’Riordan S, Connolly S, Hager H, Yu P, Becker CM, Vincent A (2008) Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 71(16):1291–1292. https://doi.org/10.1212/01.wnl.0000327606.50322.f0
doi: 10.1212/01.wnl.0000327606.50322.f0
pubmed: 18852446
Flanagan EP, McKeon A, Lennon VA, Kearns J, Weinshenker BG, Krecke KN, Matiello M, Keegan BM, Mokri B, Aksamit AJ, Pittock SJ (2011) Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology 76(24):2089–2095. https://doi.org/10.1212/WNL.0b013e31821f468f
doi: 10.1212/WNL.0b013e31821f468f
pubmed: 21670438
Diehn FE, Krecke KN (2021) Neuroimaging of spinal cord and cauda equina disorders. Continuum (Minneap Minn) 27(1):225–263. https://doi.org/10.1212/CON.0000000000000926
doi: 10.1212/CON.0000000000000926
Pittock SJ, Lennon VA (2008) Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 65(5):629–632. https://doi.org/10.1001/archneur.65.5.629
doi: 10.1001/archneur.65.5.629
pubmed: 18474738
Probasco JC, Solnes L, Nalluri A, Cohen J, Jones KM, Zan E, Javadi MS, Venkatesan A (2017) Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 4(4):e352. https://doi.org/10.1212/NXI.0000000000000352
doi: 10.1212/NXI.0000000000000352
pubmed: 28567435
pmcid: 5442608
Probasco JC, Solnes L, Nalluri A, Cohen J, Jones KM, Zan E, Javadi MS, Venkatesan A (2018) Decreased occipital lobe metabolism by FDG-PET/CT: an anti-NMDA receptor encephalitis biomarker. Neurol Neuroimmunol Neuroinflamm 5(1):e413. https://doi.org/10.1212/NXI.0000000000000413
doi: 10.1212/NXI.0000000000000413
pubmed: 29159205
Linnoila JJ (2018) Imaging in autoimmune neurology. Semin Neurol 38(3):371–378. https://doi.org/10.1055/s-0038-1660476
doi: 10.1055/s-0038-1660476
pubmed: 30011416
McKeon A, Apiwattanakul M, Lachance DH, Lennon VA, Mandrekar JN, Boeve BF, Mullan B, Mokri B, Britton JW, Drubach DA, Pittock SJ (2010) Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol 67(3):322–329. https://doi.org/10.1001/archneurol.2009.336
doi: 10.1001/archneurol.2009.336
pubmed: 20065123
Budhram A, Dubey D, Sechi E, Flanagan EP, Yang L, Bhayana V, McKeon A, Pittock SJ, Mills JR (2020) Neural antibody testing in patients with suspected autoimmune encephalitis. Clin Chem. https://doi.org/10.1093/clinchem/hvaa254
doi: 10.1093/clinchem/hvaa254
pubmed: 33221892
Ruiz-Garcia R, Martinez-Hernandez E, Saiz A, Dalmau J, Graus F (2020) The diagnostic value of onconeural antibodies depends on how they are tested. Front Immunol 11:1482. https://doi.org/10.3389/fimmu.2020.01482
doi: 10.3389/fimmu.2020.01482
pubmed: 32760403
pmcid: 7372120
Dechelotte B, Muniz-Castrillo S, Joubert B, Vogrig A, Picard G, Rogemond V, Pinto AL, Lombard C, Desestret V, Fabien N, Honnorat J (2020) Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/NXI.0000000000000701
doi: 10.1212/NXI.0000000000000701
pubmed: 32170044
pmcid: 7136063
Lang K, Pruss H (2017) Frequencies of neuronal autoantibodies in healthy controls: estimation of disease specificity. Neurol Neuroimmunol Neuroinflamm 4(5):e386. https://doi.org/10.1212/NXI.0000000000000386
doi: 10.1212/NXI.0000000000000386
pubmed: 28761905
pmcid: 5515597
Zekeridou A, Lennon VA (2019) Neurologic autoimmunity in the era of checkpoint inhibitor cancer immunotherapy. Mayo Clin Proc 94(9):1865–1878. https://doi.org/10.1016/j.mayocp.2019.02.003
doi: 10.1016/j.mayocp.2019.02.003
pubmed: 31358366
Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74(10):1216–1222. https://doi.org/10.1001/jamaneurol.2017.1912
doi: 10.1001/jamaneurol.2017.1912
pubmed: 28873125
pmcid: 5710300
Liewluck T, Kao JC, Mauermann ML (2018) PD-1 Inhibitor-associated myopathies: emerging Immune-mediated myopathies. J Immunother 41(4):208–211. https://doi.org/10.1097/CJI.0000000000000196
doi: 10.1097/CJI.0000000000000196
pubmed: 29200081
Sechi E, Markovic SN, McKeon A, Dubey D, Liewluck T, Lennon VA, Lopez-Chiriboga AS, Klein CJ, Mauermann M, Pittock SJ, Flanagan EP, Zekeridou A (2020) Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology 95(17):e2442–e2452. https://doi.org/10.1212/WNL.0000000000010632
doi: 10.1212/WNL.0000000000010632
pubmed: 32796130
pmcid: 7682911
Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, Chute DF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC (2019) Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 93(11):e1093–e1103. https://doi.org/10.1212/WNL.0000000000008091
doi: 10.1212/WNL.0000000000008091
pubmed: 31405908
Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa’ak F, Saberian C, Yee C, Davies MA, Tummala S, Woodman K, Abdel-Wahab N, Diab A (2019) Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7(1):319. https://doi.org/10.1186/s40425-019-0774-y
doi: 10.1186/s40425-019-0774-y
pubmed: 31753014
pmcid: 6868691
Vogrig A, Muniz-Castrillo S, Joubert B, Picard G, Rogemond V, Skowron F, Egri M, Desestret V, Tilikete C, Psimaras D, Ducray F, Honnorat J (2020) Cranial nerve disorders associated with immune checkpoint inhibitors. Neurology. https://doi.org/10.1212/WNL.0000000000011340
doi: 10.1212/WNL.0000000000011340
pubmed: 33318162
Vogrig A, Muniz-Castrillo S, Honnorat J (2020) Value of onconeural antibodies in checkpoint inhibitor-related toxicities. Ann Neurol 88(1):199–200. https://doi.org/10.1002/ana.25764
doi: 10.1002/ana.25764
pubmed: 32386101
Vogrig A, Muniz-Castrillo S, Desestret V, Joubert B, Honnorat J (2020) Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors. Ther Adv Neurol Disord 13:1756286420932797. https://doi.org/10.1177/1756286420932797
doi: 10.1177/1756286420932797
pubmed: 32636932
pmcid: 7318829
Gerdes LA, Held K, Beltran E, Berking C, Prinz JC, Junker A, Tietze JK, Ertl-Wagner B, Straube A, Kumpfel T, Dornmair K, Hohlfeld R (2016) CTLA4 as immunological checkpoint in the development of multiple sclerosis. Ann Neurol 80(2):294–300. https://doi.org/10.1002/ana.24715
doi: 10.1002/ana.24715
pubmed: 27351142
pmcid: 5129566